Incyte Corporation (INCY)vsRevolution Medicines Inc (RVMD)
INCY
Incyte Corporation
$127.10
-2.18%
HEALTHCARE · Cap: $23.42B
RVMD
Revolution Medicines Inc
$192.17
+6.22%
HEALTHCARE · Cap: $39.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Incyte Corporation generates 722409% more annual revenue ($5.36B vs $742,000). INCY leads profitability with a 26.7% profit margin vs 0.0%. INCY earns a higher WallStSmart Score of 72/100 (B).
INCY
Strong Buy72
out of 100
Grade: B
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+83.1%
Fair Value
$583.69
Current Price
$127.10
$456.59 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 83.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 27 of every $100 in revenue as profit
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INCY
The strongest argument for INCY centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 26.7% and operating margin at 25.6%. Revenue growth of 20.9% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : INCY
The primary concerns for INCY are PEG Ratio.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
INCY profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.38 — expect wider price swings.
INCY is growing revenue faster at 20.9% — sustainability is the question.
INCY generates stronger free cash flow (359M), providing more financial flexibility.
Bottom Line
INCY scores higher overall (72/100 vs 24/100), backed by strong 26.7% margins and 20.9% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?